治疗小儿毛细支气管炎4种不同方案的成本-效果分析

Cost-Effectiveness Analysis of Four Different Therapeutic Schemes in Treating Acute Bronchiolitis in Children

目的:评价治疗小儿毛细支气管炎4种不同方案的药物经济学效果。方法:运用药物经济学成本-效果分析法对利巴韦林静脉滴注组(A组)、炎琥宁静脉滴注组(B组)、双黄连静脉滴注组(C组)、莪术油葡萄糖静脉滴注组(D组)4种治疗方案进行回顾性分析评价。结果:4组治愈率分别为34.4%、75.7%、43.0%、76.7%(χ2=49.04,P<0.01),成本分别为1 334.84±386.40元、1 505.36±347.39元1、463.60±487.87元、1 196.76±366.74元,成本-效果比分别为38.80±11.23元、19.89±4.59元、34.04±11.35元、15.60±4.78元。结论:治疗小儿毛细支气管炎疾病,以选用D组或B组治疗方案为宜。

OBJECTIVE： To evaluate the pharmacoeconomic effects of four different therapeutic schemes in the treatment of acute bronchiolitis in children. METHODS ： The cost - effectiveness analysis was carried out on four therapeutic schemes in the treatment of acute bronchiolitis in children： Ribavirin （Group A ）, Potassium Sodium Dehydroandrographolide Succinate （Group B）, Compound Coptide （Group C）, and Zedoary Turmeric oil and Glucose （Group D）. All the drugs were administered by intravenous infusion. RESULTS ： The cure rates of the four groups were 34.4 %, 75.7 %, 43.0 % and 76.7 % （ x^2 = 49.04, P 〈 0.01 ） respectively ; the costs were （ 1 334.84 ± 386.40）, （ 1 505.36 ± 347.39）, （ 1 463.60 ± 487.87） and （ 1 196.76 ± 366.74） Yuan; the cost - effectiveness ratios were （38.80 ± 11.23）, （ 19.89 ± 4.59）, （34.04 ± 11 . 35） and （ 15.60 ± 4.78） respectively. CONCLUSION ： Group D or Group B were the preferable schemes for acute bronchiolitis in children.